Abstract: Anaphthalene ring-containing compound, a pharmaceutical composition containing same, and the use thereof. A naphthalene ring-containing compound as represented by formula III, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of the pharmaceutically acceptable salt thereof. The compound is new in structure and has a better activity on cancers.

Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Abstract: A neural network optimization method includes receiving a model file of a to-be-optimized neural network; obtaining a search space of a target neural network architecture based on the model file of the to-be-optimized neural network, where the search space includes a value range of each attribute of each neuron in the target neural network architecture; obtaining the target neural network architecture based on the search space; training the target neural network architecture based on the model file of the to-be-optimized neural network, to obtain a model file of a target neural network; and providing the model file of the target neural network to a user.

Abstract: The present invention discloses a nitroxoline derivative, a preparation method therefor, and use thereof. Specifically, the present discloses a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing same, and use thereof in treating infectious diseases or cancers. The compound of the present invention has excellent anti-tumor activity and antibacterial activity, and can be developed into a drug for treating tumors and infectious diseases. The definition of each group in general formula (I) is the same as that in the description.

Abstract: A preparation method for an aromatic ether compound. The preparation method comprises the following step: c) in a solvent, in the presence of a catalyst and alkali, a compound V reacts with a compound 6 to obtain a compound VII, wherein the solvent is a solvent system having two or more elements selected from water, tetrahydrofuran, 2-methyltetrahydrofuran, ethyl acetate, and dioxane. According to the preparation method for the aromatic ether compound in the present invention, the conversion rate of the reaction can be greatly improved, and thus the yield of the step and the total yield of the whole reaction route are improved; post-treatment and purification operations for preparing the compound VII are greatly simplified, and the compound VII having high purity can be obtained only be simply filtering a reaction solution and washing and drying a filter cake. The preparation method is suitable for industrial scale-up production.

Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Abstract: The present invention relates to a crystal form of a nitroxoline prodrug, a pharmaceutical composition containing same, and a preparation method therefor and an application thereof. An X-ray powder diffraction pattern of a crystal form A comprises characteristic peaks at 5.74±0.2°, 6.78±0.2°, 10.86±0.2°, 13.54±0.2°, 16.70±0.2°, and 22.65±0.2°; an X-ray powder diffraction pattern of a crystal form B comprises characteristic peaks at 5.44±0.2°, 10.90±0.2°, 14.09±0.2°, 16.17±0.2°, 17.92±0.2°, 20.66±0.2°, and 23.13±0.2°. Compared with nitroxoline, the crystal forms A and the B in the present application are not prone to staining, have low requirements for equipment, and are more suitable for industrial production; the stable properties are more conducive to quality control on industrial production and stability in drug efficacy.

Abstract: Disclosed herein are crystalline forms of ((2-Ethylbutanoyl)oxy)methyl (R)-2-hydroxy-3-propionamido-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylate. Also disclosed herein are methods of treating a bacterial with a crystalline form of ((2-Ethylbutanoyl)oxy)methyl (R)-2-hydroxy-3-propionamido-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylate.

Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Abstract: Provided are a nitroxoline prodrug and a use thereof. Specifically, provided are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, a composition containing the compound, and a use thereof in the preparation of anti-infective and antitumor drugs, and definitions of groups in formula (I) are as stated in the specification. The compound represented by formula (I) has better pharmacokinetic parameters such as solubility, blood medicine concentration, or half-life period than nitroxoline. The compound represented by formula (I) can reduce the frequency of drug administration, and has potential for application in other fields other than the field of urinary tracts.

Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language.

Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.

Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes.